Remove

Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10572416
Filing Date		2006-03-16
First Named Inventor	Most	
Art Unit		
Examiner Name		
Attornou Docket Numb		7601/89096

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Pat of cited Docu	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1	7002037		2006-02-21	Andersson					
	2	4081475		1978-03-28	Spivack					
	3	3721704		1973-03-20	Dexter					
If you wis	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add		
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Name of Patentee or Applicant of cited Document					Lines wher ges or Rele	
	1									
If you wis	_	dd additional U.S. Publii	shed Ap	plication citat	ion information p	please click the Ad	d button	Add		
If you wis	_	dd additional U.S. Publis		<u> </u>	ion information p		d buttor	Add		
If you wis  Examiner Initial*	h to a	dd additional U.S. Public Foreign Document Number <sup>3</sup>		FOREIGN P	ATENT DOCUM		e or	Remove Pages,Col where Rel	umns,Lines evant or Relevan	Ts

U.S. PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10572416
Filing Date		2006-03-16
First Named Inventor	Most	
Art Unit		
Examiner Name		
Attorney Docket Number		7601/88086

If you wish	h to a	dd addit	ional Fore	gn Paten	t Docun	nent citat	ion infor	mation p	lease	click the A	dd butto	Add	┙			
					NON-PA	ATENT L	ITERAT	URE DO	CUM	ENTS		Remo	ve			
Examiner Initials*	Cite No	(book,		, journal,	serial, s	ymposiu	m, catal			ficle (when pages(s), v					tem	Ţ5
	1									lective Enzy Developme						
	2									terization of ., 2003, vol.				ome		
	3		S, Reinhar propanoic A							emic Activity	y of 2-Me	thyl-2-phe	nox	y-3-		
	4		OEDERN, I ohii Collage							camate Den 1-3047.	vatives a	Inhibitors	of	Huma	si	Г
If you wis	h to a	dd addit	ional non-	patent lite	rature c	document	t citation	informat	tion ple	ease click t	he Add	outton	Add	i		_
						EXAMI	NER SIG	SNATUR	RΕ							
Examiner	Signa	ature							ı	Date Consi	idered					

See fixed Codes of USPTO Patent Documents at swee USPTO\_GDI/c or MEPF 06104. 2 Enter office that issued the document, by the No-client code (WIPO-Standard ST-3). For Laplanese patent for comments, the indication of the year of the region of the Emperor many retrieved the sensit number of the patent for sensitive comment by the appropriate symbols as indicated on the document under WIPO-Standard ST-16 if possible. 3 Applicant is to place a check mark then it Employed the Comment of the patent for sensitive sensitive or district o

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10572416
Filing Date		2006-03-16
First Named Inventor	Most	
Art Unit		
Examiner Name		
Attorney Docket Numb	ec	7601/88086

#### CERTIFICATION STATEMENT

DI	27	OFF	. 07	 4 00 4-	 appropriate	 

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

- ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael A. Sanzo/	Date (YYYY-MM-DD)	2007-04-04
Name/Brint	Minhael A. Conner	Desistration Number	26.012

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.